- Parties: The plaintiffs were Aragon Pharmaceuticals Inc. and Janssen Inc. The defendant was Sandoz Canada Inc. 

- Subject Matter: This is a patent infringement action before the Federal Court of Canada commenced by Statement of Claim dated January 2, 2025 under the Patented Medicines (Notice of Compliance) Regulations. The plaintiffs Aragon Pharmaceuticals, Inc. and Janssen Inc. allege that Sandoz Canada Inc.'s apalutamide product (in accordance with abbreviated new drug submission number 290328) will infringe Canadian Patent No. 3,128,331, while Sandoz denies infringement and counterclaims that the patent is invalid. The case is ongoing.

- Date: The hearing was set on May 19, 2026. 

- Venue: This was a federal case before the Federal Court. 

- Amount: No financial award was specified.